Jaguar Health (JAGX) Cash from Financing Activities (2014 - 2026)

Jaguar Health (JAGX) has 13 years of Cash from Financing Activities data on file, last reported at -$6.6 million in Q1 2026.

• On a quarterly basis, Cash from Financing Activities fell 233.21% year-over-year to -$6.6 million in Q1 2026; TTM through Mar 2026 was $12.1 million, a 49.42% decrease from a year earlier, with the FY2025 full-year figure at $23.7 million, down 24.14% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at -$6.6 million, down from $9.8 million in the prior quarter.
• Over the last five years, Cash from Financing Activities for JAGX reached as high as $18.8 million in Q1 2023 and fell as low as -$6.6 million in Q1 2026.
• Historically, Cash from Financing Activities has averaged $6.2 million across 5 years, with a median of $5.0 million in 2025.
• Across the five-year window, Cash from Financing Activities jumped 2620.38% in 2022 and sank 233.21% in 2026, its largest moves.
• Year by year, Cash from Financing Activities stood at $1.6 million in 2022, then soared by 550.18% to $10.6 million in 2023, then plunged by 73.43% to $2.8 million in 2024, then soared by 245.94% to $9.8 million in 2025, then sank by 167.57% to -$6.6 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were -$6.6 million in Q1 2026, $9.8 million in Q4 2025, and $6.3 million in Q3 2025.